FDA Expands Label of Oral HIV Drug to Newborns
(MedPage Today) -- The FDA expanded the approval of dolutegravir tablets for oral suspension (Tivicay PD) to include newborns with HIV infections younger than 4 weeks of age, the agency announced on Tuesday. In combination with other antiretroviral...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.